<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39455952</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2172</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>26</Day></PubDate></JournalIssue><Title>BMC immunology</Title><ISOAbbreviation>BMC Immunol</ISOAbbreviation></Journal><ArticleTitle>Chemokine CCL2 and its receptor CCR2 in different age groups of patients with COVID-19.</ArticleTitle><Pagination><StartPage>72</StartPage><MedlinePgn>72</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">72</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12865-024-00662-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Despite the development of various antiviral drugs, most of them are not effective in the treatment of coronavirus disease 2019 (COVID-19) as a hyperinflammatory disorder. Chemokine (C-C motif) ligand 2 (CCL2) is one of the critical CC chemokines involved in the pathogenesis and severity of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. This study aimed to investigate the expression of CCL2 and CC chemokine receptor 2 (CCR2) in COVID-19 patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Peripheral blood samples were collected from 60 confirmed COVID-19 patients and 60 age-matched healthy subjects. The ages of the subjects were categorized as follows: up to 20 years, 20 to 40 years, 40 to 60 years, and more than 60 years. CCL2 serum levels were measured using the enzyme-linked immunosorbent assay (ELISA). CCR2 gene expression in peripheral blood mononuclear cells (PBMCs) was measured employing real-time polymerase chain reaction (PCR).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In all age groups, CCL2 serum levels were significantly elevated in patients compared to healthy controls (P &lt; 0.0001). CCL2 levels were higher in severe patients than in moderate patients. Moreover, CCR2 expression by PBMCs was higher in patients compared to control subjects. However, a significant difference between patients and controls over 60 years of age was identified (P = 0.0353). There was no significant difference in CCR2 expression between moderate and severe COVID-19 patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Taken together, the findings demonstrate that CCL2 and CCR2 are upregulated in COVID-19 patients at protein and mRNA levels, respectively. Therefore, the CCL2/CCR2 axis may be a potential therapeutic target in order to improve patient outcomes.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bagheri</LastName><ForeName>Vahid</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khorramdelazad</LastName><ForeName>Hossein</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kafi</LastName><ForeName>Mehdi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Student Research Committee, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abbasifard</LastName><ForeName>Mitra</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. dr.mabbasifard@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Ali-Ibn Abi-Talib Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. dr.mabbasifard@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Immunol</MedlineTA><NlmUniqueID>100966980</NlmUniqueID><ISSNLinking>1471-2172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054390">Receptors, CCR2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018932">Chemokine CCL2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515334">CCR2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C111835">CCL2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054390" MajorTopicYN="Y">Receptors, CCR2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018932" MajorTopicYN="Y">Chemokine CCL2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="Y">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CCL2</Keyword><Keyword MajorTopicYN="N">CCR2</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Chemokine</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>23</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39455952</ArticleId><ArticleId IdType="doi">10.1186/s12865-024-00662-8</ArticleId><ArticleId IdType="pii">10.1186/s12865-024-00662-8</ArticleId><ArticleId IdType="pmc">PMC11515099</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sun J, He W-T, Wang L, Lai A, Ji X, Zhai X, et al. COVID-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med. 2020;26(5):483–95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118693</ArticleId><ArticleId IdType="pubmed">32359479</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang HF, Chan LWC, Cho WCS, Yu ACS, Yim AKY, Chan AKC, et al. An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Rev Anti Infect Ther. 2021;19(7):877–88.</Citation><ArticleIdList><ArticleId IdType="pubmed">33306423</ArticleId></ArticleIdList></Reference><Reference><Citation>Park M, Cook AR, Lim JT, Sun Y, Dickens BL. A systematic review of COVID-19 epidemiology based on current evidence. J Clin Med. 2020;9(4):967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7231098</ArticleId><ArticleId IdType="pubmed">32244365</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12(4):372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7232198</ArticleId><ArticleId IdType="pubmed">32230900</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SE. Epidemiology, virology, and clinical features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; coronavirus disease-19). Clin Exp Pediatr. 2020;63(4):119–24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7170784</ArticleId><ArticleId IdType="pubmed">32252141</ArticleId></ArticleIdList></Reference><Reference><Citation>Rokni M, Heidari Nia M, Sarhadi M, Mirinejad S, Sargazi S, Moudi M, et al. Association of TMPRSS2 gene polymorphisms with COVID-19 severity and mortality: a case-control study with computational analyses. Appl Biochem Biotechnol. 2022;194(8):3507–26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8986508</ArticleId><ArticleId IdType="pubmed">35386063</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Lan Z, Ye J, Pang L, Liu Y, Wu W, et al. Cytokine storm: the primary determinant for the pathophysiological evolution of COVID-19 deterioration. Front Immunol. 2021;12:589095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8115911</ArticleId><ArticleId IdType="pubmed">33995341</ArticleId></ArticleIdList></Reference><Reference><Citation>Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020;53:66–70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7204669</ArticleId><ArticleId IdType="pubmed">32418715</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosroshahi LM, Rokni M, Mokhtari T, Noorbakhsh F. Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview. Int Immunopharmacol. 2021;93:107364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7784533</ArticleId><ArticleId IdType="pubmed">33486333</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidari Nia M, Rokni M, Mirinejad S, Kargar M, Rahdar S, Sargazi S, et al. Association of polymorphisms in tumor necrosis factors with SARS-CoV‐2 infection and mortality rate: a case‐control study and in silico analyses. J Med Virol. 2022;94(4):1502–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9015227</ArticleId><ArticleId IdType="pubmed">34821383</ArticleId></ArticleIdList></Reference><Reference><Citation>Rokni M, Ghasemi V, Tavakoli Z. Immune responses and pathogenesis of SARS-CoV‐2 during an outbreak in Iran: comparison with SARS and MERS. Rev Med Virol. 2020;30(3):e2107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7235481</ArticleId><ArticleId IdType="pubmed">32267987</ArticleId></ArticleIdList></Reference><Reference><Citation>Rokni M, Ahmadikia K, Asghari S, Mashaei S, Hassanali F. Comparison of clinical, para-clinical and laboratory findings in survived and deceased patients with COVID-19: diagnostic role of inflammatory indications in determining the severity of illness. BMC Infect Dis. 2020;20:869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7680983</ArticleId><ArticleId IdType="pubmed">33225909</ArticleId></ArticleIdList></Reference><Reference><Citation>Rokni M, Hamblin MR, Rezaei N. Cytokines and COVID-19: friends or foes? Hum Vaccine Immunother. 2020;16(10):2363–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7644241</ArticleId><ArticleId IdType="pubmed">32841579</ArticleId></ArticleIdList></Reference><Reference><Citation>Sargazi S, Sheervalilou R, Rokni M, Shirvaliloo M, Shahraki O, Rezaei N. The role of autophagy in controlling SARS-CoV‐2 infection: an overview on virophagy‐mediated molecular drug targets. Cell Biol Int. 2021;45(8):1599–612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8251464</ArticleId><ArticleId IdType="pubmed">33818861</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagheri V. Pharmacological targeting of HMGB-1 translocation: a potential therapeutic strategy for COVID-19. Pharmacol Res. 2022;184:106455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9477604</ArticleId><ArticleId IdType="pubmed">36116707</ArticleId></ArticleIdList></Reference><Reference><Citation>Rokni M, Sarhadi M, Heidari Nia M, Mohamed Khosroshahi L, Asghari S, Sargazi S, et al. Single nucleotide polymorphisms located in TNFA, IL1RN, IL6R, and IL6 genes are associated with COVID-19 risk and severity in an Iranian population. Cell Biol Int. 2022;46(7):1109–27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9347541</ArticleId><ArticleId IdType="pubmed">35521908</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassanshahi G, Arababadi MK, Khoramdelazad H, Yaghini N, Zarandi ER. Assessment of CXCL12 (SDF-1α) polymorphisms and its serum level in posttransfusion occult HBV-infected patients in Southeastern Iran. Arch Med Res. 2010;41(5):338–42.</Citation><ArticleIdList><ArticleId IdType="pubmed">20851290</ArticleId></ArticleIdList></Reference><Reference><Citation>Aminzadeh F, Ghorashi Z, Nabati S, Ghasemshirazi M, Arababadi MK, Shamsizadeh A, et al. Differential expression of CXC chemokines CXCL 10 and CXCL 12 in term and pre-term neonates and their mothers. Am J Reprod Immunol. 2012;68(4):338–44.</Citation><ArticleIdList><ArticleId IdType="pubmed">22738089</ArticleId></ArticleIdList></Reference><Reference><Citation>Azin H, Vazirinejad R, Ahmadabadi BN, Khorramdelazad H, Zarandi ER, Arababadi MK, et al. The SDF-1 3′ a genetic variation of the chemokine SDF-1α (CXCL12) in parallel with its increased circulating levels is associated with susceptibility to MS: a study on Iranian multiple sclerosis patients. J Mol Neurosci. 2012;47:431–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22125123</ArticleId></ArticleIdList></Reference><Reference><Citation>Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25–32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211650</ArticleId><ArticleId IdType="pubmed">32446778</ArticleId></ArticleIdList></Reference><Reference><Citation>Pum A, Ennemoser M, Adage T, Kungl AJ. Cytokines and chemokines in SARS-CoV-2 infections—therapeutic strategies targeting cytokine storm. Biomolecules. 2021;11(1):91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7828218</ArticleId><ArticleId IdType="pubmed">33445810</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranjbar M, Rahimi A, Baghernejadan Z, Ghorbani A, Khorramdelazad H. Role of CCL2/CCR2 axis in the pathogenesis of COVID-19 and possible treatments: all options on the table. Int Immunopharmacol. 2022;113:109325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9561120</ArticleId><ArticleId IdType="pubmed">36252475</ArticleId></ArticleIdList></Reference><Reference><Citation>Moadab F, Khorramdelazad H, Abbasifard M. Role of CCL2/CCR2 axis in the immunopathogenesis of rheumatoid arthritis: latest evidence and therapeutic approaches. Life Sci. 2021;269:119034.</Citation><ArticleIdList><ArticleId IdType="pubmed">33453247</ArticleId></ArticleIdList></Reference><Reference><Citation>Vakilian A, Khorramdelazad H, Heidari P, Rezaei ZS, Hassanshahi G. CCL2/CCR2 signaling pathway in glioblastoma multiforme. Neurochem Int. 2017;103:1–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">28025034</ArticleId></ArticleIdList></Reference><Reference><Citation>Behfar S, Hassanshahi G, Nazari A, Khorramdelazad H. A brief look at the role of monocyte chemoattractant protein-1 (CCL2) in the pathophysiology of psoriasis. Cytokine. 2018;110:226–31.</Citation><ArticleIdList><ArticleId IdType="pubmed">29277337</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbasifard M, Khorramdelazad H. Harmonizing hope: navigating the osteoarthritis melody through the CCL2/CCR2 axis for innovative therapeutic avenues. Front Immunol. 2024;15:1387651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11284107</ArticleId><ArticleId IdType="pubmed">39076996</ArticleId></ArticleIdList></Reference><Reference><Citation>Arfaei R, Mikaeili N, Daj F, Boroumand A, Kheyri A, Yaraghi P, et al. Decoding the role of the CCL2/CCR2 axis in Alzheimer’s disease and innovating therapeutic approaches: keeping all options open. Int Immunopharmacol. 2024;135:112328.</Citation><ArticleIdList><ArticleId IdType="pubmed">38796962</ArticleId></ArticleIdList></Reference><Reference><Citation>Taghavi Y, Hassanshahi G, Kounis NG, Koniari I, Khorramdelazad H. Monocyte chemoattractant protein-1 (MCP-1/CCL2) in diabetic retinopathy: latest evidence and clinical considerations. J Cell Commun Signal. 2019;13(4):451–62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946768</ArticleId><ArticleId IdType="pubmed">30607767</ArticleId></ArticleIdList></Reference><Reference><Citation>National Health Commission &amp; National Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 7). Chin Med J. 2020;133(9):1087–95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7213636</ArticleId><ArticleId IdType="pubmed">32358325</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil BA, Elemam NM, Maghazachi AA. Chemokines and chemokine receptors during COVID-19 infection. Comput Struct Biotechnol J. 2021;19:976–88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7859556</ArticleId><ArticleId IdType="pubmed">33558827</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanatidou V, Zaravinos A, Apostolakis S, Spandidos DA. Chemokines in respiratory viral infections: focus on their diagnostic and therapeutic potential. Crit Rev Immunol. 2011;31(4):341–56.</Citation><ArticleIdList><ArticleId IdType="pubmed">21899514</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin J, Lin J, Xu A, Lou J, Qian C, Li X, et al. CCL2: an important mediator between tumor cells and host cells in tumor microenvironment. Front Oncol. 2021;11:722916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8354025</ArticleId><ArticleId IdType="pubmed">34386431</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton ST, Scott GM, Naing Z, Rawlinson WD. Human cytomegalovirus directly modulates expression of chemokine CCL2 (MCP-1) during viral replication. J Gen Virol. 2013;94(11):2495–503.</Citation><ArticleIdList><ArticleId IdType="pubmed">23939977</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider D, Hong JY, Bowman ER, Chung Y, Nagarkar DR, McHenry CL, et al. Macrophage/epithelial cell CCL2 contributes to rhinovirus-induced hyperresponsiveness and inflammation in a mouse model of allergic airways disease. Am J Physiol Lung Cell Mol Physiol. 2013;304(3):L162–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3567365</ArticleId><ArticleId IdType="pubmed">23204071</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbatucci M, Covino DA, Purificato C, Mallano A, Federico M, Lu J, et al. Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation. Retrovirology. 2015;12:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4314729</ArticleId><ArticleId IdType="pubmed">25608886</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C, Wang K, Zhao Z, Zhang L, Gu H, Yang P, et al. CC motif chemokine ligand 2 (CCL2) mediates acute lung injury induced by lethal influenza H7N9 virus. Front Microbiol. 2017;8:587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5379033</ArticleId><ArticleId IdType="pubmed">28421067</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagheri-Hosseinabadi Z, Shamsizadeh A, Bahrehmand F, Abbasifard M. Evaluation of the relationship between serum interleukin-1β levels and expression of inflammasome-related genes in patients with COVID-19. BMC Immunol. 2023;24(1):30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10507843</ArticleId><ArticleId IdType="pubmed">37723427</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivarria G, Lane TE. Evaluating the role of chemokines and chemokine receptors involved in coronavirus infection. Expert Rev Clin Immunol. 2022;18(1):57–66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8851429</ArticleId><ArticleId IdType="pubmed">34964406</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26(6):842–44.</Citation><ArticleIdList><ArticleId IdType="pubmed">32398875</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):761–70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7170362</ArticleId><ArticleId IdType="pubmed">32228226</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi Y, Ge Y, Wu B, Zhang W, Wu T, Wen T, et al. Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019 in China. J Infect Dis. 2020;222(5):746–54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7337752</ArticleId><ArticleId IdType="pubmed">32563194</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z-S, Shu T, Kang L, Wu D, Zhou X, Liao B-W, et al. Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients. Signal Transduct Target Ther. 2020;5(1):100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7303571</ArticleId><ArticleId IdType="pubmed">32561706</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D, Nilsson-Payant BE, Liu W-C, Uhl S, Hoagland D, Møller R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Abers MS, Delmonte OM, Ricotta EE, Fintzi J, Fink DL, de Jesus AAA, et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight. 2021;6(1):e144455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7821609</ArticleId><ArticleId IdType="pubmed">33232303</ArticleId></ArticleIdList></Reference><Reference><Citation>Tincati C, Cannizzo ES, Giacomelli M, Badolato R, d’Arminio Monforte A, Marchetti G. Heightened circulating interferon-inducible chemokines, and activated pro-cytolytic Th1-cell phenotype features Covid-19 aggravation in the second week of illness. Front Immunol. 2020;11:580987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7606391</ArticleId><ArticleId IdType="pubmed">33193384</ArticleId></ArticleIdList></Reference><Reference><Citation>Coperchini F, Chiovato L, Ricci G, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: further advances in our understanding the role of specific chemokines involved. Cytokine Growth Factor Rev. 2021;58:82–91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7837329</ArticleId><ArticleId IdType="pubmed">33573850</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Nilsson-Payant BE, Han Y, Jaffré F, Zhu J, Wang P, et al. Cardiomyocytes recruit monocytes upon SARS-CoV-2 infection by secreting CCL2. Stem Cell Rep. 2021;16(9):2274–88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8289700</ArticleId><ArticleId IdType="pubmed">34403650</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Chen L, Gao Y, Li M, Wang X, Qiang L, et al. Recent advances targeting C-C chemokine receptor type 2 for liver diseases in monocyte/macrophage. Liver Int. 2020;40(12):2928–36.</Citation><ArticleIdList><ArticleId IdType="pubmed">33025657</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson TC, Beck MA, Kuziel WA, Henderson F, Maeda N. Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza a virus. Am J Pathol. 2000;156(6):1951–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850091</ArticleId><ArticleId IdType="pubmed">10854218</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S-J, Lo M, Kuo R-L, Shih S-R, Ojcius DM, Lu J, et al. The pathological effects of CCR2 + inflammatory monocytes are amplified by an IFNAR1-triggered chemokine feedback loop in highly pathogenic influenza infection. J Biomed Sci. 2014;21(1):99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4243311</ArticleId><ArticleId IdType="pubmed">25407417</ArticleId></ArticleIdList></Reference><Reference><Citation>van Helden MJ, Zaiss DM, Sijts AJ. CCR2 defines a distinct population of NK cells and mediates their migration during influenza virus infection in mice. PLoS ONE. 2012;7(12):e52027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3521727</ArticleId><ArticleId IdType="pubmed">23272202</ArticleId></ArticleIdList></Reference><Reference><Citation>Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. Genetic mechanisms of critical illness in COVID-19. Nature. 2021;591(7848):92–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">33307546</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharif-Zak M, Abbasi-Jorjandi M, Asadikaram G, Ghoreshi ZA, Rezazadeh-Jabalbarzi M, Afsharipur A, et al. CCR2 and DPP9 expression in the peripheral blood of COVID-19 patients: influences of the disease severity and gender. Immunobiology. 2022;227(2):152184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8806394</ArticleId><ArticleId IdType="pubmed">35131543</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng K-Y, Han J, Zhang X, Hsu S-H, He S, Wani NA, et al. Blocking the CCL2–CCR2 axis using CCL2-neutralizing antibody is an effective therapy for hepatocellular cancer in a mouse model. Mol Cancer Ther. 2017;16(2):312–22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5292068</ArticleId><ArticleId IdType="pubmed">27980102</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Yao W, Yuan Y, Chen P, Li B, Li J, et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut. 2017;66(1):157–67.</Citation><ArticleIdList><ArticleId IdType="pubmed">26452628</ArticleId></ArticleIdList></Reference><Reference><Citation>Winter C, Silvestre-Roig C, Ortega-Gomez A, Lemnitzer P, Poelman H, Schumski A, et al. Chrono-pharmacological targeting of the CCL2-CCR2 axis ameliorates atherosclerosis. Cell Metab. 2018;28(1):175–82.</Citation><ArticleIdList><ArticleId IdType="pubmed">29861387</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto M, Toyama M, Baba M. The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;182:104902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392080</ArticleId><ArticleId IdType="pubmed">32739404</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderheiden A, Thomas J, Soung AL, Davis-Gardner ME, Floyd K, Jin F, et al. CCR2 signaling restricts SARS-CoV-2 infection. mBio. 2021;12(6):e0274921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8576528</ArticleId><ArticleId IdType="pubmed">34749524</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>